Neuropharmacology of AMPA and kainate receptors.
Bleakman
D
D
Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. bleakman_david@lilly.com
Lodge
D
D
D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy; D018690:Excitatory Amino Acid Agonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000378:metabolism; D010146:Pain / Q000188:drug therapy; D018091:Receptors, AMPA / Q000187:drug effects* / Q000378:metabolism; D018092:Kainic Acid Receptors / Q000187:drug effects* / Q000378:metabolism
D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA; D018092:Kainic Acid Receptors